Created by AIM at Melanoma, the Melanoma Learning Center is a virtual hub for all types of melanoma education. This page provide reliable, relevant, and current information about all aspects of melanoma for patients, families, healthcare professionals, caregivers, and others interested in the disease. Click here to access the Melanoma Learning Center #ClinicalTrials #Melanoma #WebPage #CollaborativePartner #SideEffects #RegisteredNurse #Patient #PatientAdvocate #2018 #AIMatMelanoma
Rapid Update v3.1 Summary The information below provides an overview of update v3.1 to the " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0 " published in Journal for ImmunoTherapy of Cancer (JITC) . The FDA granted accelerated approval to lifileucel (autologous tumor-infiltrating lymphocyte therapy) for adult patients with unresectable or metastastic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive a BRAF inhibitor with or without a MEK inhibitor in February 2024. Based on this approval, the Melanoma v3.0 CPG has been updated in the following locations: "Stage IV cutaneous melanoma – Patients with CNS Disease," "Stage IV cutaneous melanoma – Available agents and indications for previously-treated disease," and "Special patient populations - Patients with non-cutaneous melanoma."
From the Cancer Support Community, learn about the use of cytokines, ipilimumab (a CTLA-4 inhibitor), and PD-1 Inhibitors as well as the future of immunotherapy for melanoma. Click here to read, "Immunotherapy for Melanoma" #ClinicalTrials #WebPage #AdverseEvents #SideEffects #Melanoma #Cytokines #ImmuneCheckpointInhibitors #PatientAdvocate #Patient #CollaborativePartner #CancerSupportCommunity(CSC)
Curated by AIM at Melanoma, learn about FDA (U.S. Food and Drug Administration) approved drugs for melanoma , as well as suggestions for managing the side effects associated with these drugs. Click here to learn more about FDA Approved Drugs for Melanoma #Melanoma #WebPage #CollaborativePartner #CombinationTherapy #Cytokines #ImmuneCheckpointInhibitors #Ipilimumab #Nivolumab #Pembrolizumab #Vaccines #Patient #PatientAdvocate #AIMatMelanoma
One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally renowned cancer centers across the United States to provide patient-friendly information on new developments, innovative advances in melanoma treatment options, and emerging therapies
Beginning in 2010, AIM at Melanoma began partnering with nationally renowned cancer centers across the United States to provide patient-friendly information on new developments, innovative advances in melanoma treatment options, and emerging therapies
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us